We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
Accept
Home » Aurobindo Scolded Yet Again for Manufacturing Violations
Aurobindo Scolded Yet Again for Manufacturing Violations
The FDA has cracked down once more on Indian pharma giant Aurobindo Pharma for manufacturing deficiencies at one of its facilities, slamming the company with yet another Form 483 over drugmaking violations and quality unit concerns.